Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Share-based Compensation (2022 - 2025)

BioXcel Therapeutics has reported Share-based Compensation over the past 4 years, most recently at $450000.0 for Q4 2025.

  • Quarterly results put Share-based Compensation at $450000.0 for Q4 2025, up 326.13% from a year ago — trailing twelve months through Dec 2025 was $2.3 million (down 62.49% YoY), and the annual figure for FY2025 was $2.8 million, down 55.05%.
  • Share-based Compensation for Q4 2025 was $450000.0 at BioXcel Therapeutics, down from $581000.0 in the prior quarter.
  • Over the last five years, Share-based Compensation for BTAI hit a ceiling of $6.1 million in Q2 2023 and a floor of -$199000.0 in Q4 2024.
  • Median Share-based Compensation over the past 4 years was $3.5 million (2023), compared with a mean of $2.8 million.
  • Biggest five-year swings in Share-based Compensation: crashed 105.53% in 2024 and later soared 326.13% in 2025.
  • BioXcel Therapeutics' Share-based Compensation stood at $4.5 million in 2022, then decreased by 20.85% to $3.6 million in 2023, then plummeted by 105.53% to -$199000.0 in 2024, then soared by 326.13% to $450000.0 in 2025.
  • The last three reported values for Share-based Compensation were $450000.0 (Q4 2025), $581000.0 (Q3 2025), and $1.1 million (Q2 2025) per Business Quant data.